PLSH · XBRL financial data

Panacea Life Sciences Holdings financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PLSH's year ends in late December)

In thousands of dollars	Q2 FY21Jun 30, 2021	Q3 FY21†Sep 30, 2021	Q4 FY21Dec 31, 2021	Q1 FY22Mar 31, 2022	Q2 FY22Jun 30, 2022	Q3 FY22Sep 30, 2022	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024
Revenue	313	588	646*	466	—	—	year only	—	—	—	—	—
Revenue from contracts with customers	313	588	646*	466	469	366	325*	677	399	348	960*	1,056
Cost of revenue	249	305	636*	366	332	319	214*	452	196	201	414*	390
Gross profit	65	283	10*	100	138	47	111*	226	203	147	547*	666
General and administrative	335	291	607*	461	205	262	167*	247	145	277	787*	249
Total operating expenses	1,504	1,541	2,158*	1,748	1,378	1,436	1,486*	1,516	1,277	1,561	2,315*	1,724
Other operating income (expense)	—	—	—	—	28	0*	0*	—	—	—	—	—
Operating income (loss)	(1,439)	(1,258)	(2,148)*	(1,648)	(1,240)	(1,389)	(1,376)*	(1,290)	(1,074)	(1,414)	(1,768)*	(1,057)
Interest expense	284	175	324*	501	570	598	379*	380	367	397	412*	430
Other income (expense)	1,692	(1,832)	—	—	—	—	—	—	—	—	—	—
Income tax expense (benefit)	1	—	—	—	—	—	—	—	—	—	—	—
Net income (loss)	27	(3,090)	(2,091)*	(2,782)	(1,962)	(2,694)	(1,705)*	(1,791)	(1,864)	(2,151)	(2,209)*	(1,446)
Earnings per share, basic USD per share	0.00	(0.14)	—	(0.19)	(0.13)	(0.18)	(0.11)*	(0.12)	(0.11)	(0.13)	(0.13)*	(0.09)
Earnings per share, diluted USD per share	0.00	(0.14)	—	(0.19)	(0.13)	(0.18)	—	(0.12)	(0.11)	(0.13)	(0.13)*	(0.09)
Weighted average shares, basic thousands of shares	16,916	21,389	—	14,762	14,862	14,862	14,960*	14,862	17,645	16,618	17,357*	16,493
Weighted average shares, diluted thousands of shares	16,916	21,389	—	14,762	14,965	14,862	14,858*	14,965	17,645	16,618	17,256*	16,493

† Share count changed about 1/43 in the period ending 2021-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (PLSH's year ends in late December)

In thousands of dollars	Q2 FY21Jun 30, 2021	Q3 FY21†Sep 30, 2021	Q4 FY21Dec 31, 2021	Q1 FY22Mar 31, 2022	Q2 FY22Jun 30, 2022	Q3 FY22Sep 30, 2022	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024
Cash and cash equivalents	131	15	20	56	37	37	7	73	8	1	101	108
Marketable securities	6,005	3,632	3,791	2,847	2,562	1,116	1,107	925	460	78	15	10
Accounts receivable	290	515	244	163	220	222	206	275	272	309	264	271
Inventory	4,273	4,344	4,264	4,325	4,480	4,412	4,449	4,095	4,358	4,692	4,014	4,063
Prepaid and other current assets	102	194	278	234	320	197	113	79	149	293	263	192
Total current assets	11,301	9,200	9,098	8,124	8,119	6,484	6,382	5,947	5,748	5,873	4,656	4,643
Property and equipment, net	9,431	9,025	8,840	8,543	8,208	7,965	7,676	7,269	6,855	6,874	6,448	6,070
Right-of-use asset	3,768	3,682	3,595	3,508	3,420	3,332	3,242	3,153	3,062	2,971	3,865	3,686
Goodwill	2,189	2,189	2,189	2,189	2,189	2,189	2,189	2,189	2,189	3,014	3,014	3,014
Total assets	26,780	24,171	23,784	22,410	21,966	19,984	19,489	18,557	17,854	18,733	17,983	17,413
Accrued liabilities	—	—	—	—	—	—	283	—	593	—	—	—
Total current liabilities	8,731	9,299	10,071	11,557	13,064	13,815	15,074	15,890	17,047	18,536	19,448	20,392
Lease liability, non-current	3,521	3,435	3,347	3,258	3,169	3,078	2,987	2,894	2,801	2,706	3,254	3,070
Total liabilities	15,295	15,776	16,681	18,229	19,712	20,424	21,634	22,358	23,421	24,815	26,275	27,035
Accumulated deficit	(11,585)	(14,675)	(16,765)	(19,547)	(21,509)	(24,203)	(25,908)	(27,699)	(29,563)	(31,714)	(33,923)	(35,369)
Total stockholders' equity	11,485	8,395	7,102	4,181	2,254	(440)	(2,145)	(3,801)	(5,567)	(6,083)	(8,291)	(9,623)
Total liabilities and equity	26,780	24,171	23,784	22,410	21,966	19,984	19,489	18,557	17,854	18,733	17,983	17,413
Common shares outstanding (cover page) thousands of shares	599,005	14,074	14,762	14,965	14,965	14,965	14,762	15,505	17,645	17,645	17,645	17,645

† Share count changed about 1/43 in the period ending 2021-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (PLSH's year ends in late December)

In thousands of dollars	Q2 FY21Jun 30, 2021	Q3 FY21†Sep 30, 2021	Q4 FY21Dec 31, 2021	Q1 FY22Mar 31, 2022	Q2 FY22Jun 30, 2022	Q3 FY22Sep 30, 2022	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024
Net income (loss)	27	(3,090)	(2,091)*	(2,782)	(1,962)	(2,694)	(1,705)*	(1,791)	(1,864)	(2,151)	(2,209)*	(1,446)
Net cash from operating activities	(1,914)*	(753)*	(1,230)*	(436)	(729)*	(711)*	(523)*	(314)	(483)*	(729)*	2*	(357)
Purchases of property and equipment	99*	(14)*	(9)*	10	8*	127*	99*	15	9*	—	year only	5
Net cash from investing activities	269*	244*	9*	(10)	39*	(127)*	(99)*	(15)	(9)*	(23)*	(18)*	(5)
Net cash from financing activities	1,697*	392*	1,226*	482	671*	839*	592*	395	428*	745*	116*	369
Net change in cash	33*	(116)*	5*	36	(19)*	0*	(30)*	66	(65)*	(7)*	99*	7

† Share count changed about 1/43 in the period ending 2021-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Panacea Life Sciences Holdings	108	1,056	(357)	17.6M	0.3 quarters	Q1 FY24 10-QMar 31, 2024
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Celldex Therapeutics	47,454	22	(57,410)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
America Great Health	29	26	1.7*	21.2B	—	Q3 FY26 10-QMar 31, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Kaya Holdings	26	5.4	(68)*	686.4M	0.4 quarters	Q3 FY25 10-QSep 30, 2025
One World Products	169	50	(145)*	120.1M	1.2 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.